The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat

被引:7
作者
Besret, L
Page, KJ
Dunnett, SB
机构
[1] Cardiff Univ, Sch Biosci, Cardiff CF1 3US, S Glam, Wales
[2] Univ Cambridge, MRC, Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England
基金
英国医学研究理事会;
关键词
D-1 and D-2 receptors; haloperidol; mRNA; locomotor activity; autoradiography;
D O I
10.1016/S0006-8993(99)02311-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
It has been demonstrated that withdrawal from chronic treatment with haloperidol is associated with a long-lasting increase in the number of striatal dopamine D-2, receptors and variable changes in D-1, receptors. We have investigated the effect of withdrawal from sub-chronic administration of haloperidol on the density of dopamine receptors, dopamine receptor gene expression, and spontaneous locomotor activity. Following a 3-week treatment period with haloperidol (1.5 mg/kg, i.p.), spontaneous locomotor activity measurements, autoradiography of D-1, and D-2, receptors and in situ hybridisation histochemistry of D-1, and D-2, mRNA were performed, Using [H-3]raclopride as the ligand, sub-chronic haloperidol administration produced a robust upregulation in D-2 binding in the striatum of rats which correlated with parallel increases in spontaneous locomotor activity from 24 h to 4 weeks. Using, [H-3]SCH23390 as the Ligand, D1 binding was largely unaffected by the drug treatment. Non-significant changes were measured in the striatal expression of D-1, receptor mRNA or the nigral or striatal expression of D-2, receptor mRNA, Our findings have implications for the use of dopaminergic ligands in positron emission tomography (PET) imaging of patients under regimens of chronic neuroleptics in particular in the context of forthcoming trials of neural grafts in Huntington's disease (HD) striatum. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:125 / 135
页数:11
相关论文
共 51 条
[1]  
[Anonymous], 1991, HUNTINGTONS DIS
[2]   [11C]raclopride-PET studies of the Huntington's disease rate of progression:: Relevance of the trinucleotide repeat length [J].
Antonini, A ;
Leenders, KL ;
Eidelberg, D .
ANNALS OF NEUROLOGY, 1998, 43 (02) :253-255
[3]   Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease [J].
Antonini, A ;
Leenders, KL ;
Spiegel, R ;
Meier, D ;
Vontobel, P ;
WeigellWeber, M ;
SanchezPernaute, R ;
deYebenez, JG ;
Boesiger, P ;
Weindl, A ;
Maguire, RP .
BRAIN, 1996, 119 :2085-2095
[4]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[5]   Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes [J].
Bäckman, L ;
Robins-Wahlin, TB ;
Lundin, A ;
Ginovart, N ;
Farde, L .
BRAIN, 1997, 120 :2207-2217
[6]   SERUM HALOPERIDOL CONCENTRATION AND CHOREIFORM MOVEMENTS IN HUNTINGTONS-DISEASE [J].
BARR, AN ;
FISCHER, JH ;
KOLLER, WC ;
SPUNT, AL ;
SINGHAL, A .
NEUROLOGY, 1988, 38 (01) :84-88
[7]   EFFECTS OF SINGLE AND LONG-TERM HALOPERIDOL ADMINISTRATION ON OPEN-FIELD BEHAVIOR OF RATS [J].
BERNARDI, MM ;
DESOUZA, H ;
NETO, JP .
PSYCHOPHARMACOLOGY, 1981, 73 (02) :171-175
[8]  
Bjorklund A., 1994, FUNCTIONAL NEURAL TR, P157
[9]   PET-BASED AND MRI-BASED ASSESSMENT OF GLUCOSE-UTILIZATION, DOPAMINE-RECEPTOR BINDING, AND HEMODYNAMIC-CHANGES AFTER LESIONS TO THE CAUDATE-PUTAMEN IN PRIMATES [J].
BROWNELL, AL ;
HANTRAYE, P ;
WULLNER, U ;
HAMBERG, L ;
SHOUP, T ;
ELMALEH, DR ;
FRIM, DM ;
MADRAS, BK ;
BROWNELL, GL ;
ROSEN, BR ;
ISACSON, O .
EXPERIMENTAL NEUROLOGY, 1994, 125 (01) :41-51
[10]   LINEAR PHARMACOKINETICS OF HALOPERIDOL IN THE RAT [J].
CHENG, YF ;
PAALZOW, LK .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1992, 13 (01) :69-76